Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Immunology
Tong Liu, Shuai Jiang, Xue Teng, Lu Zhong, Mengmeng Liu, Yao Jin, Mei Dong
Summary: In the treatment of metastatic colorectal cancer, there was no significant difference in overall survival, progression free survival, and response rate between cetuximab and panitumumab. However, there were differences in adverse reactions, with decreased incidence of paronychia in the panitumumab arm and decreased incidence of hypomagnesemia in the cetuximab arm.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
(2023)
Article
Oncology
Jonathan M. Loree, Yucai Wang, Muddassir A. Syed, Alexey Sorokin, Oluwadara Coker, Joanne Xiu, Benjamin A. Weinberg, Ari M. Vanderwalde, Anteneh Tesfaye, Victoria M. Raymond, Benjamin Miron, Gabi Tarcic, Ori Zelichov, Russell R. Broaddus, Patrick Kwok Shing Ng, Kang Jin Jeong, Yiu Huen Tsang, Gordon B. Mills, Michael J. Overman, Axel Grothey, John L. Marshall, Scott Kopetz
Summary: The study identified a high prevalence of atypical RAS mutations in colorectal cancer patients, which were associated with poor prognosis. Activating atypical variants were the most common in clinical cohorts, providing the best evidence to guide treatment.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Luca Mastrantoni, Viria Beccia, Giulia Caira, Giovanni Trovato, Maria Alessandra Calegari, Michele Basso, Lisa Salvatore, Carmelo Pozzo, Giampaolo Tortora, Emilio Bria, Armando Orlandi
Summary: This study investigated maintenance therapy options for RAS wild type metastatic colorectal cancer. The results showed that FP + anti-EGFR treatment had the longest progression-free survival and was relatively safe. Anti-EGFR monotherapy may be considered for patients with left-sided tumors.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Oncology
Yi-Hsin Liang, Kuo-Hsing Chen, Yu-Yun Shao
Summary: Adding anti-EGFR mAb to first-line chemotherapy for KRAS wild-type mCRC is associated with significantly longer overall survival and time to treatment failure, especially in left-sided primary tumors.
Article
Medicine, General & Internal
Rona Yaeger, Jared Weiss, Meredith S. Pelster, Alexander Spira, Minal Barve, Sai-Hong Ou, Ticiana A. Leal, Tanios S. Bekaii-Saab, Cloud P. Paweletz, Grace A. Heavey, James G. Christensen, Karen Velastegui, Thian Kheoh, Hirak Der-Torossian, Samuel J. Klempner
Summary: In this study, the researchers investigated the clinical efficacy of adagrasib in combination with cetuximab for heavily pretreated patients with metastatic colorectal cancer harboring mutant KRAS G12C. The results showed that the overall response rate was 19% in the adagrasib monotherapy group, with a median progression-free survival of 5.6 months, and 46% in the combination therapy group, with a median progression-free survival of 6.9 months. Both groups experienced reversible adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Multidisciplinary Sciences
Peng Ye, Peiling Cai, Jing Xie, Yuanyuan Wei
Summary: This study investigated the accuracy of digital polymerase chain reaction, amplification refractory mutation system, and next-generation sequencing in detecting KRAS mutation in cell-free DNA samples from colorectal cancer patients, showing that these methods have overall high accuracy.
Review
Medicine, General & Internal
Gerardo Rosati, Michele Montrone, Carmen Pacilio, Alfredo Colombo, Giuseppe Cicero, Fernando Paragliola, Angelo Vaia, Luigi Annunziata, Domenico Bilancia
Summary: Although colorectal cancer is increasingly diagnosed in older patients, their representation in clinical trials is insufficient, leading to unclear treatment guidelines. Targeted therapy for elderly patients with wild-type RAS and BRAF is challenging due to potential toxicity. Comprehensive geriatric assessment and recent studies provide important data for differentiating treatment outcomes based on functional status.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang
Summary: The purpose of this study is to determine the impact of KRAS gene mutations on the efficacy of panitumumab monotherapy for metastatic colorectal cancer (mCRC). Through testing on 463 patients, it was found that 43% of patients had KRAS mutations. The results showed that panitumumab significantly improved overall survival and progression-free survival for patients with wild-type KRAS, while no significant efficacy was observed for patients with KRAS mutations. Therefore, KRAS status should be taken into account when selecting mCRC patients for panitumumab monotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Alessandro Parisi, Michele Ghidini, Riccardo Giampieri, Gianluca Tomasello, Andrea Luciani, Claudio Ferri, Rossana Berardi, Fausto Petrelli
Summary: Limited data is available on the efficacy of post-induction strategies using anti-EGFR treatment in patients with metastatic colorectal cancer (mCRC). This systematic review and meta-analysis found that CT+anti-EGFR treatment significantly prolonged overall survival (OS) and progression-free survival (PFS) compared to other agents or observation. Maintenance treatment with anti-EGFR + FP may be a better option for mCRC patients following anti-EGFR based induction treatment.
CLINICAL COLORECTAL CANCER
(2022)
Article
Oncology
Marinde J. G. Bond, Karen Bolhuis, Olaf J. L. Loosveld, Jan Willem B. de Groot, Helga Droogendijk, Helgi H. Helgason, Mathijs P. Hendriks, Joost M. Klaase, Geert Kazemier, Mike S. L. Liem, Arjen M. Rijken, Cornelis Verhoef, Johannes H. W. de Wilt, Koert P. Jong, Michael F. Gerhards, Martinus J. van Amerongen, Marc R. W. Engelbrecht, Krijn P. van Lienden, I. Quintus Molenaar, Bart de Valk, Brigitte C. M. Haberkorn, Emile D. Kerver, Frans Erdkamp, Robbert J. van Alphen, Danielle Mathijssen-van Stein, Aysun Komurcu, Marta Lopez-Yurda, Rutger-Jan Swijnenburg, Cornelis J. A. Punt, Dutch Colorectal Canc Study Grp
Summary: This study compared the efficacy of different induction regimens in patients with initially unresectable colorectal cancer liver metastases. The results showed that FOLFOXIRI-bevacizumab was the preferred treatment for patients with right-sided primary tumor or RAS/BRAFV600E mutation, while the addition of panitumumab to FOLFOX or FOLFIRI in patients with left-sided and RAS/BRAFV600E wild-type tumor showed no clinical benefit but more toxicity.
Article
Biochemistry & Molecular Biology
Joris van de Haar, Xuhui Ma, Salo N. Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, Nicoletta Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Maria Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F. A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri
Summary: Genomic analysis identified KRAS(G12) mutations as potential biomarkers of resistance to trifluridine/tipiracil treatment in metastatic colorectal cancer. Real-world data and phase 3 clinical trial data confirmed the significant association between KRAS(G12) mutations and reduced overall survival. These findings provide important implications for precision medicine in approximately 28% of patients with metastatic colorectal cancer.
Article
Oncology
Chengren Zhang, Lili Liu, Yaochun Lv, Jingjing Li, Cong Cao, Jiyong Lu, Shuai Wang, Binbin Du, Xiongfei Yang
Summary: The meta-analysis showed that for wild-type KRAS/RAS metastatic colorectal cancer patients, EGFR inhibitors were superior to VEGF inhibitors in prolonging overall survival and overall response rate, with no significant difference in progression-free survival. The survival benefit of EGFR inhibitors was mainly observed in first-line treatment.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Review
Genetics & Heredity
Stavroula Koilakou, Panagiotis Petrou
Summary: Colorectal cancer is a major global health issue with metastatic CRC having improved survival rates due to advanced biologic therapies. However, the cost-effectiveness of monoclonal antibodies in mCRC treatment varies, with bevacizumab showing lower cost-effectiveness in both first-line and maintenance treatment compared to cetuximab or panitumumab in certain subgroups. RAS testing prior to anti-EGFR treatment is recommended for cost-effective treatment strategies.
MOLECULAR DIAGNOSIS & THERAPY
(2021)
Review
Pharmacology & Pharmacy
Zaina T. Al-Salama
Summary: Encorafenib in combination with cetuximab has shown significantly longer overall survival, higher response rate, and better tolerability in patients with mCRC and a BRAF V600E mutation who have had prior therapy.
Article
Substance Abuse
James H. Conigrave, Kristie H. Harrison, K. S. Kylie Lee, Timothy A. Dobbins, Beth Hummerston, Noel Hayman, Jimmy Perry, Rowena Ivers, Paul S. Haber, Scott Wilson, David Johnson, Katherine M. Conigrave
Summary: The study showed that providing training and support for Aboriginal Community Controlled Health Services can improve alcohol screening rates.
Review
Pharmacology & Pharmacy
Juliana de Oliveira Costa, Claudia Bruno, Navya Baranwal, Natasa Gisev, Timothy A. Dobbins, Louisa Degenhardt, Sallie-Anne Pearson
Summary: The study found a wide variation in definitions of long-term opioid therapy (LTOT), with the most common definition being 90 days of use within a year. Lack of detailed description of LTOT definitions in the studies hindered reproducibility and impacted the comparability of research findings.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Immunology
Jialing Lin, Timothy Dobbins, James G. Wood, Carla Bernardo, Nigel P. Stocks, Bette Liu
Summary: This study assessed the effectiveness of herpes zoster vaccine in the Australian population aged 70-79 years old. The vaccine showed a higher effectiveness in the first year but declined in the second year. Age, sex, comorbid conditions, and prior GP visit frequency did not impact vaccine effectiveness.
Article
Substance Abuse
Chrianna Bharat, Sarah Larney, Sebastiano Barbieri, Timothy Dobbins, Nicola R. Jones, Matthew Hickman, Natasa Gisev, Robert Ali, Louisa Degenhardt
Summary: The study found that retention in buprenorphine treatment for opioid dependence in New South Wales, Australia has improved over time since its introduction in 2001. Treatment retention is not only influenced by characteristics of the person and their treatment, but also by prescriber characteristics, with longer prescribing tenure associated with increased retention of people in opioid agonist treatment.
Article
Health Care Sciences & Services
Andrea L. Schaffer, Timothy A. Dobbins, Sallie-Anne Pearson
Summary: ARIMA modeling is a useful approach for evaluating the impact of large-scale interventions, especially when dealing with seasonality and autocorrelation. It can account for underlying trends, allow for flexible modeling of different impacts, and provide valuable insights for policy evaluation.
BMC MEDICAL RESEARCH METHODOLOGY
(2021)
Article
Substance Abuse
Alison Ritter, Katinka van de Ven, Thu Vuong, Jenny Chalmers, Timothy Dobbins, Michael Livingston, Lynda Berends
Summary: This study found no significant associations between procurement and funding contract arrangements and client outcomes for alcohol and drug treatment services. However, treatment length of stay may be associated with AOD workforce and case-loads, while receiving services from a government provider may be associated with lower treatment completion rates.
Article
Substance Abuse
Monika Dzidowska, K. S. Kylie Lee, James H. Conigrave, Timothy A. Dobbins, Beth Hummerston, Scott Wilson, Paul S. Haber, Dennis Gray, Katherine M. Conigrave
Summary: This study demonstrates that an early support model can increase alcohol screening rates in Aboriginal health services. However, the impact on treatment outcomes is less clear.
Article
Genetics & Heredity
Sarah Norris, Andrea Belcher, Kirsten Howard, Robyn L. Ward
Summary: MSAC is an independent committee established by the Australian government to provide recommendations on public reimbursement of non-pharmaceutical technologies and services. Their recent publication on clinical utility cards for genetic testing identified methodological and policy challenges, including how to incorporate patient and societal preferences for genomic testing outcomes in global health technology assessments.
JOURNAL OF COMMUNITY GENETICS
(2022)
Article
Substance Abuse
Janni Leung, Vivian Chiu, Nicola Man, Wing See Yuen, Timothy Dobbins, Adrian Dunlop, Natasa Gisev, Wayne Hall, Sarah Larney, Sallie-Anne Pearson, Louisa Degenhardt, Amy Peacock
Summary: In New South Wales, Australia, individuals who had an alcohol-related hospital inpatient or emergency department presentation between 2005 and 2014 had a higher risk of mortality than the general population during the same period.
Article
Immunology
Jonathan M. King, Kathy Petoumenos, Timothy Dobbins, Rebecca J. Guy, Richard T. Gray, Steven J. Nigro, Damin Si, Byron Minas, Skye McGregor
Summary: Australia aims to eliminate HIV transmission by the end of 2022, but there is a lack of accurate information on HIV transmission among residents. The researchers developed a method to estimate the timing of HIV acquisition among migrants to Australia. They found that almost half of migrants diagnosed with HIV acquired the infection after arrival in Australia, underscoring the need for tailored testing and prevention programs.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
(2023)
Article
Substance Abuse
Andrea L. Schaffer, Natasa Gisev, Fiona M. Blyth, Nicholas A. Buckley, David Currow, Timothy A. Dobbins, Andrew Wilson, Louisa Degenhardt, Sallie-Anne Pearson
Summary: We analyzed opioid prescribing patterns among medical practitioners in New South Wales, Australia from 2013 to 2018. Our findings revealed substantial variations in opioid prescribing, which were clustered into four general patterns. Some prescribing patterns were concerning and may potentially harm patients. These findings provide insights for targeted interventions to address potentially harmful practices.
DRUG AND ALCOHOL REVIEW
(2023)
Article
Substance Abuse
James H. Conigrave, Emma K. Devine, K. S. Kylie Lee, Timothy Dobbins, Julia Vnuk, Noel Hayman, Katherine Conigrave
Summary: This study explored the impact of COVID-19 lockdowns on the rate of screening for risky drinking in Aboriginal Community Controlled Health Services in Australia. The findings suggest that the screening rate significantly decreased in urban and inner regional areas during the lockdowns, while there was no significant change in other regions. As harm from alcohol consumption may have increased during the lockdowns, policymakers should consider ways to continue screening for risky drinking during future lockdowns.
DRUG AND ALCOHOL REVIEW
(2023)
Meeting Abstract
Substance Abuse
Chrianna Bharat, Sarah Larney, Sebastiano Barbieri, Timothy Dobbins, Nicola R. Jones, Matthew Hickman, Natasa Gisev, Robert Ali, Louisa Degenhardt
DRUG AND ALCOHOL REVIEW
(2021)
Meeting Abstract
Substance Abuse
Nicola R. Jones, Matthew Hickman, Sarah Larney, Suzanne Nielsen, Robert Ali, Timothy Dobbins, David A. Fiellin, Louisa Degenhardt
DRUG AND ALCOHOL REVIEW
(2021)
Meeting Abstract
Substance Abuse
Wing See Yuen, Janni Leung, Nicola Man, Vivian Chiu, Natasa Gisev, Michael Livingston, Louisa Degenhardt, Michael Farrell, Sallie-Anne Pearson, Timothy Dobbins, Adrian J. Dunlop, Richard P. Mattick, Amy Peacock
DRUG AND ALCOHOL REVIEW
(2021)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)